2/16/2024 0 Comments Advanced diagnostic laboratory![]() 22/05/12 Advanced Diagnostics Supports use of new Roche HER2 Teaching Resource.Representatives from Advanced Diagnostics/London Cancer & BCUK attend parliamentary briefing to discuss the importance of targeted testing and personalised medicine, with a specific focus on colorectal cancer, KRAS testing and Cetuximab. Now open for recruitment, OPTIMA is a partially-blind randomised trial designed to compare clinical and economic outcomes of standard chemotherapy treatment with biomarker-directed allocation to chemotherapy or no chemotherapy in women with ER positive, HER2 negative breast cancer and either axillary node involvement or larger tumours'.Ģ2/05/12 Advanced Diagnostics Attends Parliamentary Briefing on Targeted Cancer Diagnostics & Personalised Medicine 24/10/12 Advanced Diagnostics Begins Centralised Testing for Major Clinical Trial. ![]() HSL Advanced Diagnostics is now offering PD-L1 IHC testing using the Dako pharmDx 22C3 companion diagnostic for Pembrolizumab.Ģ8/01/13 Advanced Diagnostics Validates New ALK IHC Assay for NSCLCĪdvanced Diagnostics validates the new Roche Tissue Diagnostics ALK IHC assay for use in Non Small Cell Lung Cancer (NSCLC) patients for whom Crizotinib (Xalkori, Pfizer) is being considered. 25/08/16 PD-L1 22C3 EAMS Reference Laboratory.Our UKAS customer number is 9007 and our scope of accreditation can be found here.ġ4/12/16 Advanced Diagnostics Accreditation StatusĪfter a successful UKAS assessment on the 13th & 14th of December 2016, the Advanced Diagnostics laboratories are very happy to announce that we are currently "Recommended for Accreditation" to UKAS/ISO15189:2012 standards. 27/10/17 Advanced Diagnostics are please to inform that we have received accreditation by UKAS to ISO15189:2012 standardsĪdvanced Diagnostics are please to inform that we have received accreditation by UKAS to ISO15189:2012 standards.30/06/18 Advanced Diagnostics Validates New ROS1 IHC Assay for NSCLCįollowing approval from NICE to allow access to Crizotonib for ROS1 positive patients with NSCLC, Advanced Diagnostics have made available a validated ROS1 IHC assay to all referring clients.Ģ6/04/18 Advanced Diagnostics joins Health Services Laboratories pathology joint venture organisationįrom the 1st May 2018 we are pleased to announce the creation of HSL Advanced Diagnostics.We are pleased to inform you that from 30th March, 2020 HSL-Advanced Diagnostics will operate from our new and permanent location at 60 Whitfield Street Please contact the laboratory if you are planning on referring a significant amount of additional work.ģ0/03/20 HSL Advanced Diagnostics Laboratory Move The HSL-AD service is able to take in additional referral work to help maintain services under pressure.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |